Maddi Hebebrand, MC, Associate Editor

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

The guidelines formalize a stepwise treatment approach ranging from emollients and topical steroids to systemic therapies.

The newly published tool, ODD-SPOT, offers a plain-language, photo-supported alternative to the ABCDE criteria, designed to capture the key warning signs of BCC, SCC, and melanoma in accessible terms.

Among systemic-experienced patients, delgocitinib cream still achieved statistically significant efficacy advantages over cream vehicle across all measured outcomes.

The combination of rapid onset and durable response positions zumilokibart as a potentially attractive first-line biologic option.

A cross-sectional study of 403 acne patients found that higher impulsivity scores were significantly associated with both the presence and severity of acne scars.

Around 80% of clinical trials face enrollment delays, and for rare genodermatoses with small patient pools, AI-generated synthetic control arms may offer a practical path to adequately powered studies.

Patients who are needle-averse may soon have effective non-injectable options with biologic-like results.

Steven Daveluy, MD, discusses how this approval helps close a critical gap in care for adolescents living with HS.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Mohammad Jafferany, MD, discuss how integrating mental health and dermatologic care can improve outcomes for patients with chronic skin conditions.

Hoth Therapeutics has received regulatory approval in Hungary to expand the phase 2 trial into Europe, with Spain and Poland approvals anticipated.

LPP affects roughly 100,000 adults in the US and currently has no FDA-approved treatments.

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

The combination therapy SHORE trial produced the highest response rates of the 3 studies, with EASI-75 approaching 48% in the Q4W arm.

The trial’s results may support earlier use of dual IL-17A/F inhibitors in patients with both skin and joint disease.

Dermatology Times is recapping our exclusive expert interviews from the month of March.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Three-year BE HEARD EXT data confirm that bimekizumab's clinical responses deepen over time, with HiSCR90 rates rising from 42% at year 1 to 64% at year 3.

Eight in ten ADlong patients achieved clinical response without steroid rescue, strengthening the case for lebrikizumab as a standalone, long-term management option.

The FDA has granted Priority Review to brepocitinib's NDA for dermatomyositis, with a Q3 2026 PDUFA date that could make it the first drug specifically approved for this indication.

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.

This year’s AAD poster awards highlight studies advancing skin cancer prevention, inflammatory disease management, and complex dermatology care.

BE HEARD extension data underscore the importance of early diagnosis and treatment initiation to optimize long-term outcomes in hidradenitis suppurativa.

With 80% of trial participants being children, this analysis provides some of the most robust early-response data available for a non-steroidal topical in pediatric AD.

The GLODERM Pre–AAD meeting emphasized that global skin health progress now depends on translating policy into scalable, equitable care delivery.